Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Opioids
Biotech
AstraZeneca cans ph. 2 OUD drug over antifungal interaction
AstraZeneca ended work on the orexin 1 receptor antagonist after it demonstrated a drug-drug interaction with an antifungal during a phase 2 trial.
James Waldron
Nov 22, 2024 4:41am
With 4 remaining staffers, CNS-focused Trevena nears end of road
Nov 7, 2024 10:40am
FDA approves first DNA test for opioid use disorder risks
Dec 21, 2023 10:18am
Click, Indivior to make digital therapeutics for addiction
Sep 8, 2023 1:13pm
FDA clears Masimo’s opioid overdose prevention monitor
Apr 3, 2023 9:31am
Eagle swoops down to nab chunk of BARDA-backed Enalare
Aug 9, 2022 11:22am
